Literaturverzeichnis


Alsenz J, Steffen H, Alex R: Active apical secretory efflux of the HIV protease inhibitors saquinavir and ritonavir in Caco-2 cell monolayers. Pharm Res. 1998, 15 (3), S.423-428,


Azzaria M, Schurr E, Gros P: Discrete mutations induced in the predicted nucleotide-binding sites of the mdr1 gene abolish its ability to confer multidrug resistance. Mol Cell Biol. 1989, 9 (12), S.5289-5297,


Bernal ML, Sinues B, Fanlo A, Mayayo E: Frequency distribution of C3435T mutation in exon 26 of the MDR1 gene in a Spanish population. Ther Drug Monitor. 2003, 25 (1), S.107-111,

Biondi A, Vasecchi MG, Seriu T et al.: Molecular detection of minimal residual disease is a strong predictive factor of relapse in childhood B-lineage acute lymphoblastic leukemia with medium risk features. A case control study of the International BFM study group. Leukemia. 2000, 14, S.1939-1943,


Chang TKH, Yu L, Goldstein JA, Waxman DJ: Identification of the polymorphically expressed CYP2C19 and the wild-type CYP2C9-ILE359 allele as low-Km catalysts of cyclophosphamide and ifosfamide activation. Pharmacogenetics. 1997, 7, S.211-221,

Chen CJ, Chin JE, Ueda K et al.: Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug resistance cells. Cell. 1986, 47, S.381-389,


Cholerton S, Daly AK, Idle JR: The role of individual human cytochromes P450 in drug metabolism and clinical response. Trends Pharmacol Sci. 1992, 13 (12), S.434-439,


Collett A, Higgs NB, Sims E, Rowland M, Warhurst G: Modulation of the permeability of H2 receptor antagonists cimetidine and ranitidine by P-glycoprotein in rat intestine and the human colonic cell line Caco-2. J Pharmacol Exp Ther. 1999, 288 (1), S.171-178,


Cvetkovic M, Leake B, Fromm MF, Wilkinson GR, Kim RB: OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of faxofenadine. Drug Metab Dispos. 1999, 27 (8), S.866-871,


Gray IC, Nobile C, Muresu R, Ford S, Spurr NK: A 2.4-megabase physical map spinning the CYP2C gene cluster on chromosome 10q24. Genomics. 1995, 28 (2), S.328-332,

Greaves MF, Alexander FE: An infectious etiology for common acute lymphoblastic leukemia in childhood?. Leukemia. 1993, 7, S.349-360,


Guengerich FP, Kim DH: In vitro inhibition of dihydropyridine oxidation and aflatoxin B1 activation in human liver microsomes by naringenin and other flavonoids. Carcionogenesis. 1990, 11 (12), S.2275-2279,


Hamada H, Tsuruo T: Functional role for the 170 to180-kDa glycoprotein specific to drug-resistant tumour cells as revealed by monoclonal antibodies. Proc Natl Acad Sci USA. 1986, 3 (20), S.7785-7789,


Harbott J, Ritterbach J, Ludwig WD, Bartram CR, Reiter A, Lampert F: Clinical significance of cytogenetic studies in childhood acute lymphoblastic leukemia: experience of the BFM trials. Recent Results Cancer Res. 1993, 131,
Harrison DJ: Molecular mechanisms of drug resistance in tumours. Journal of Pathology. 1995, 175, S.7-12,


Hayaishi O: Biological oxidations. Annu Rev Biochem. 1962, 31, S.24-46,


Inoue K, Yamazaki H, Shimada T: Linkage between the distribution of mutations in the CYP2C18 and CYP2C19 genes in the Japanese and Caucasian. Xenobiotica. 1998, 28 (4), S.403-411,


Kartner N, Riordan JR, Ling V: Cell surface P-glycoprotein associated with multidrug resistance in mammalian cell lines. Science. 1983, 221, S.1285-1288,

Kato GJ, Quddus FF, Shuster JJ, Boyett J, Pullen JD, Borowitz MJ, Whitehead VM, Crist WM, Leventhal BG: High glucocorticoid receptor content of leukemic blasts is a favorable prognostic factor in childhood acute lymphoblastic leukemia. Blood. 1993, 82, S.2304-2309,


Klingenberg M: Pigments of rat liver microsomes. Arch Biochem Biophys. 1958, 75 (2), S.376-386,

Klose TS, Blaisdell JA, Goldstein JA: Gene structure of CYP2C8 and extrahepatic distribution of human CYP2Cs. J Biochem Mol Toxicol. 1999, 13 (6), S.289-295,


Lankas GR, Wise LD, Cartwright ME, Pippert T, Umbenhauer DR: Placental P-glycoprotein deficiency enhances susceptibility to chemically induced birth defects in mice. Reprod Toxicol. 1998, 12, S.457-463,


Liu J, Liu Y, Powell DA, Waalkes MP, Klaassen CD: Multidrug-resistance mdr1a/1b double knockout mice are more resistant than wild type mice to acute arsenic toxicity, with higher arsenic accumulation in tissues. Toxicology. 2002, 170 (1-2), S.55-62,


Mancy A, Antignac M, Minoletti C, Dijols S, Mouries V, Duong NT, Battoni P, Dansette PM, Mansuy D: Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites.
particular efficiency and regioselectivity of P450 2Cs. Biochemistry. 1999, 38, S.14264-14270,


Mason HS: Mechanisms of oxygen metabolism. Science. 1957, 125 (3259), S.1185-1188,


Meyer UA: The molecular basis of genetic polymorphisms of drug metabolism. J Pharm. 1994, 46, S.409-415,


Nakamura T, Sakaeda T, Harinouchi M, Tamura T, Aoyama N, Shirakawa T, Matsuo M, Kasuga M, Okumura K: Effects of the mutation (C3435T) at exon 26 of the MDR1 gene on expression


Nedelcheva V, Gut I: P450 in the rat and man: methods of investigation, substrate specificities and relevance to cancer. Xenobiotica. 1994, 24 (12), S.1151-1175,


Relling MV: Are the major effects of P-glycoprotein modulators due to altered pharmacokinetics of anticancer drugs?. Ther Drug Monit. 1996, 18, S.350-356,


Roy P, Yu LJ, Crespi CL, Waxman DJ: Development of a substrate-activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles. Drug Metab Dispos. 1999, 27 (6), S.655-666,


Sawyers CL: Molecular genetics of acute leukemia. Lancet. 1997, Vol. 349; 9042, S.196-200,


Schoenlein PV, Shen DW, Barrett JT, Pastan I, Gottesman MM: Double minute chromosomes carrying the human multidrug resistance 1 and 2 genes are generated from the dimerization of submicroscopic circular DNAs in colchicine-selected KB carcinoma cells. Mol Biol Cell. 1992, 3 (5), S.507-520,


Schuetz EG, Schinkel AH, Relling MV, Schuetz JD: P-glycoprotein: a major determinant of rifampicin inducible expression of cytochrome P450 3A in mice and humans. Proc Natl Acad Sci USA. 1996, 93 (9), S.4001-4005,


van Kalken CK, Pinedo HM, Giaccone G: Multidrug resistance from the clinical point of view. Eur J Cancer. 1991, 27 (11), S.1481-1486,


Wheeler K, Chessells JM, Bailey CC, Richards S: Treatment-related deaths during induction and first remission in childhood ALL. Med Pediatr Oncol. 1994, 23 (4), S.A26,

Wilkinson GR, Guengerich FP, Branch RA: Genetic polymorphism of S-mephenytoin hydroxylation. Pharmacol Ther. 1989, 43 (1), S.53-76,


Yang JM, Vassil AD, Hait WN: Activation of phospholipase C induces the expression of the multidrug resistance (MDR1) gene through the Raf-MAPK pathway. Mol Pharmacol. 2001, 60 (4), S.674-680,

Yengi LG, Xiang Q, Pan J, Scatina J, Kao J, Ball SE, Fruncillo R, Ferron G, Roland Wolf C: Quantification of cytochrome P450 mRNA levels in human skin. Anal Biochem. 2003, 103-110,


Zaphiropoulos PG: Exon skipping and circular RNA formation in transcripts of the human cytochrome P450 2C18 gene in epidermis and of the rat androgen binding protein gene in testis. Mol Cell Biol. 1997, 17 (6), S.2985-2993,

Zhu-Ge J, Yu YN, Li X, Qian YL: Cloning of cytochrome P450 2C9 cDNA from human liver and its expression in CHL cells. World of Gastroenterol. 2002, 8, S.318-322,